Objective: C-type natriuretic peptide (CNP), which is produced by vascular endothelial cells, exhibits anti-proliferative and antiinflammatory effects. Cytotoxic T-lymphocytes may be involved in vein graft disease. Attenuation of vein graft disease necessitates a remodelling of the arterialized vein towards a more contractile phenotype which is characterized, among other factors, by the calponin amount. We investigated the effects of perivascularly applied CNP in a mouse model of vein graft disease. Methods: C57BL6J mice underwent interposition of the inferior vena cava from isogenic donor mice into the common carotid artery using a previously described cuff technique. In the treatment group, 10 26 mol/l of CNP were applied locally in pluronic gel. The control group did not receive local treatment. Grafts were harvested at 1, 2, 4, and 8 weeks and underwent morphometric analysis as well as immunohistochemical analysis. Results: In grafted veins without treatment (controls) median intimal thickness was 10 (6-29), 12 (8 -40) mm, was 47 (12 -58), and 79 (62 -146) mm after 1, 2, 4 and 8 weeks, respectively. In the treatment groups, which received 10 26 mol/l of CNP, the intimal thickness was 5 (3 -6), 6 (4 -15), 32 (5 -54), and 43 (39-70) mm after 1, 2, 4 and 8 weeks, respectively. This reduction of intimal thickness was significant at 1, 2 and 8 weeks. Immunohistochemically, the reduction of intimal thickness was associated with a decreased infiltration of CD-8 positive cells and an increased amount of calponin in the CNP-treated grafts. Conclusion: We conclude that perivascular application of CNP inhibits neointimal hyperplasia of vein grafts in a mouse model. These results suggest that CNP may have a therapeutic potential for the prevention of vein graft disease. q
Introduction
Early injury and late degeneration are responsible for the occlusion of venous bypass grafts. One important early pathological feature of veins implanted into the arterial circulation is the formation of neointimal hyperplasia. In conjunction with an inflammatory component the development of vein graft atherosclerosis is eased [1 -3] .
C-type natriuretic peptide (CNP) is produced by vascular endothelial cells and consists of 22 amino acids. Besides vasodilatory properties, CNP inhibits proliferation of vascular smooth muscle cells and shows anti-inflammatory and anti-thrombotic effects [4, 5] . CNP binds to natriuretic peptide receptor B, which inhibits a guanylyl cyclase activity. CNP increases the amount of cyclic guanosine monophosphate in human internal thoracic arteries and saphenous veins [6, 7] . In arterial injury models, CNP showed an inhibitory effect on formation of neointimal hyperplasia [8, 9] .
CD8 markers are found on cytotoxic T-lymphocytes which recognize major histocompatibility complex class-I bound antigens [10] . Their major cytotoxic effector molecules are perforin, granzymes, and tumor necrosis factor. Cytotoxic T-lymphocytes mediate vascular injury in graft versus host disease [11] . An interesting finding is that cytotoxic T-lymphocytes are activated following myocardial infarction and can recognize and kill healthy myocytes in vitro [12] . In human stenotic aortocoronary saphenous vein grafts, accumulations of T-lymphocytes are found which are thought to be involved in immune reactions leading to progression of graft atherosclerosis [13] .
Calponin is a smooth muscle specific protein which plays a role in thin filament-based regulation of smooth muscle contraction [14] . Calponin belongs to the differentiation markers of smooth muscle cells.
It was the aim of this study to test the hypothesis that cytotoxic T-lymphocytes are involved in vein graft disease and that perivascularly applied CNP has an effect on neointimal hyperplasia in vein grafts in a mouse model. And we wanted to test if a reduction of neointimal hyperplasia is associated with a remodelling of the arterialized vein graft towards a more contractile phenotype as determined by the calponin and alpha smooth muscle actin amount.
This mouse model for vein graft disease was developed at our University [15] . Pluronic-127 gel has been demonstrated to be an effective carrier for a drug and does not influence neointimal hyperplasia in this animal model [16] .
Material and methods

Mice and vein grafting
Three-month-old male C57BL/6J mice were purchased from Harlan-Winkelmann (Borchen, Germany). They were maintained at 24 8C and received food and water ad libitum. All procedures were performed according to protocols approved by the Austrian Ministry of Science according to Section 8 of the law on animal experiments and all animals were treated according to the 'Guide for the Use and Care of Laboratory Animals', published by the National Institutes of Health (NIH publication no. 85-23, revised 1985).
The operation was performed as previously described [15] . In brief, the inferior vena cava was harvested from an isogenic donor mouse and stored in cold Ringer's lactate solution. In the recipient mouse, the right common carotid artery was exposed, ligated, divided and the two stumps were everted over a nylon cuff. The vein from the donor mouse was then interposed between the carotid artery cuffs.
CNP application and tissue preparation
In the treatment groups, 10 26 mol/l of CNP were applied perivascularly around the grafted vein. As a carrier, we used 0.1 ml of 20% Pluronic-F-127e gel (BASF, Germany). The control group did not receive local treatment.
For histological analysis, the animals underwent autopsy 1, 2, 4 and 8 weeks postoperatively. The grafts were perfusion-fixed with 4% phosphate buffered formaldehyde via puncture of the left ventricle as described previously [15] . The interposed vein segments were cut out at the cuff ends and were fixed with 4% phosphate-buffered formaldehyde. Due to the small size of the grafts, they were embedded in a piece of mouse liver tissue. Consecutively, the compounds were formalin-fixed and paraffin embedded.
Histology and lesion quantification
Four micrometre thick sections were cut and were Elastica van Gieson stained for measurement of the intimal thickness. Digital photomicrographs of all vessels were taken using a SONY DSC-70 camera with a resolution of 2048 £ 1586 pixels with a colour depth of 24 bits per pixel in RGB. The microscope used was a Zeiss Axioplan with Plan Flourit optics and a fotoadapter. For getting an overview picture, a 10 £ magnification objective was used. The zoom objective of the camera was adjusted to full zoom, and afterwards reduced by three microsteps. For measurements, a 20 £ magnification objective was used with the same camera adjustment.
All photographs were saved in JPEG format. The measurements were done using OPTIMAS 5.0 image analysis software on an IBM compatible PC. For reproducibility reasons, the overview pictures were used to mark the exact locations where the thickness measurements were taken.
The intimal thickness measurements were performed by two experienced observers (T.M. and A.O.). For achieving a reproducible result, the cross-sections of the veins were divided into four quadrants. In each quadrant three measurements were made. The mean value of all measurements was regarded as representative for the intimal thickness.
Immunohistochemistry
Immunohistochemistry was carried out on paraffin embedded sections of animals 4 weeks postoperatively. The following primary antibodies were used: mouse anti-CD-8 (clone C8/144B IgG1-k, Dako Inc., Glostrup, Denmark) for detection of T-lymphocytes, mouse antimetallothionin (clone E9 IgG1-k, Dako Inc., Glostrup, Denmark), mouse anti-smooth muscle actin (IgG1, Biogenex Inc., San Ramon, CA), mouse anti-platelet derived growth factor receptor a (PDGFRa) (Santa Cruz Biotechnology, CA), mouse anti-calponin (IgG1, Sigma Inc., Vienna, Austria). The sections were visualized using NexES IHC w automatic immunohistochemical stainer (Ventana Medical Systems, Tucson, AZ) with diaminobenzidine basic kit (Ventana Medical Systems, Tucson, AZ).
The results were quantified by a pathologist (A.T.) by counting the number of positively staining cells in highpower fields (400 £ magnification; 0.189 mm 2 /field). The number of counted cells was extrapolated to 0.2 mm 2 . Staining intensity was not quantified, but only intensities at least two times stronger than background have been taken into consideration. Since cellular borders of migrated myofibroblasts were hardly ever to be defined, the total area of SMA positive patches was evaluated. In the case of metallothionein and PDGFRa expression in the neointima, only a description analysis was performed, since the staining was not confined to cells but to the matrix.
Statistical analysis
The SPSS software (SPSS 10.0) for windows was used for statistical analysis. Neointimal thickness is given as median and range. Comparisons between histological measurements of the intimal thickness were made by Mann -Whitney U test. Results were considered statistically significant at P values of less than 0.05.
Results
The intimal thickness in native veins was 1.6 (1.3 -2.4) mm. Neointimal hyperplasia developed in all vein grafts (Fig. 1) respectively, compared with controls. The difference to controls was statistically significant at 1, 2 and 8 weeks.
Thrombus formation in the vein grafts occurred in no case after 2 weeks. After 4 weeks, thrombi were found in 2/7 (29%) control veins and in 1/9 (11%) CNP-treated veins.
Immunohistochemical staining with anti-calponin antibody showed a predominant expression in the adventitia. In the CNP-treated group, the amount of calponin positive cells was significantly increased as compared with controls ( Fig. 2a and b ; Table 1 ).
Immunohistochemical staining with anti-CD-8 antibody showed an adventitial distribution of CD-8 positive cells, whereas in the neointima no CD-8 positive cells were found. In the CNP-treated group, the number of CD-8 positive cells was significantly reduced compared with controls ( Fig. 2c  and d ; Table 1 ).
Immunohistochemical staining with anti-PDGFRa antibody showed a strong expression in the neointima, media, and adventitia. The amount of PDGFRa positive cells in the media of CNP-treated vein grafts was reduced by 53% compared with controls. The amount of PDGFRa positive cells in the adventitia of CNP-treated vein grafts was increased by 29% compared with controls. These differences between the two groups in the amount of PDGFRa positive cells, however, did not reach statistical significance (Table 1) .
Immunohistochemical staining with anti-metallothionein antibody showed a clear expression in the neointima and adventitia. The amount of metallothionein corresponded with the thickness of neointima and adventitia and there was no quantitative difference between controls and CNP-treated groups. However, the amount of positively staining cells in the media of the controls exceeded that in the media of CNP-treated animals ( Table 1) . Immunohistochemical staining with anti-smooth muscle actin antibody showed a clear expression predominantly in the neointima and only little in the media and adventitia. There were no significant differences in the average areas of SMA-positive patches between the groups (Table 1 ).
Discussion
In our experiments, we demonstrated an inhibitory effect of CNP on the development of neointimal hyperplasia in an established mouse model. The reduction was about 60% in the first 2 weeks and about 40% after 8 weeks. Yasuda and co-workers demonstrated that endoluminally applied CNP inhibits neointimal formation in a rabbit iliac artery balloon injury model [9] . One advantage of CNP is its small peptide size which makes it a candidate for use in gene therapy. Ueno and co-workers have shown that local expression of CNP after transfection into injured rat carotid arteries reduced neointimal formation [8] . Ohno and co-workers found decreased thrombus formation and reduced neointimal thickness in rabbit jugular vein grafts transfected with CNP expressing Adenovirus compared with Lac Z expressing Adenovirus transfected controls. But there was a high rate of mural thrombi of 80% after 2 weeks and 100% after 4 weeks in the Lac Z expressing controls [17] . In our study, thrombi occurred in no vein after 2 weeks and in 29% of the controls versus 11% of the CNP-treated veins after 4 weeks.
Calponin is a smooth muscle specific protein which can bind to actin, tropomyosin, Ca 2þ -calmodulin and myosin. It plays a role in thin filament-based regulation of smooth muscle contraction [27] . Calponin belongs to the differentiation markers of smooth muscle cells. Wolf and co-workers have demonstrated that growing coronary artery collaterals show a weak expression of calponin in the neointima, whereas after remodeling into mature, and thicker vessels the neointima contained more calponin [28] .
We found an increase of calponin positive cells in CNP-treated vein grafts which was 16-fold the amount of calponin positive cells in the control group. These findings would be consistent with remodelling of the vein graft towards a more mature contractile type of vessel under the treatment with CNP.
All control vein grafts showed the presence of CD8 positive cells, whereas in CNP-treated veins they were almost completely absent. Inflammatory cell infiltration of the vein graft, which occurs early in the postoperative course is an important pathogenetic factor for neointimal hyperplasia [18] . Cherian and co-workers investigated human stenotic aortocoronary saphenous vein grafts and found an accumulation of T-lymphocytes, which are thought to be involved in immune reactions leading to progression of graft atherosclerosis [13] . In accordance with these data, we found an adventitial infiltration of the grafted veins with CD8 positive lymphocytes which were reduced in veins treated with CNP.
Different growth factors are associated with the development of neointimal hyperplasia one of which is platelet derived growth factor (PDGF) [3, 19] . PDGF stimulates migration and proliferation and it inhibits apoptosis. There are two different protein subunits that form either homodimers (PDGF-AA, PDGF-BB) or heterodimers (PDGF-AB). There are two corresponding receptors (PDGFRa, PDGFRb). All PDGF isoforms can bind to PDGFRa, whereas PDGF-AA and PDGF-AB cannot bind to PDGFRb [19] . In native human saphenous veins, PDGFRa expression is less than expression of PDGFRb [20] . Sirois and co-workers found that both, PDGFRa and PDGFRb, were overexpressed in balloon injured rat carotid arteries 2 weeks after injury [21] . PDGFR blockade inhibited intimal hyperplasia in balloon injury models [22, 23] , thus suggesting a role in vein graft disease too. We found a strong presence of PDGFRa positive cells in controls as well as in CNP-treated veins. The amount of PDGFRa positive cells in the media of CNP-treated animals showed a trend towards reduction compared with controls.
Metallothionein is a highly conserved, ubiquitously expressed low molecular weight protein. The expression of metallothionein is induced by heavy metals, heat, inflammation and other stress conditions. Kang and co-workers demonstrated that metallothionein inhibits ischemia reperfusion injury in the mouse heart [24] . Metallothioneins can protect against oxidative damage by scavenging harmful oxygen radicals which can be generated by activated leucocytes [14] . In our study, we found a reduced metallothionein amount in the media of CNP-treated vein grafts compared with controls, whereas in the adventitia there was no difference in the metallothionein amount between the two groups. An interesting finding was that metallothionein was more often found in the neointima and in the adventitia than in the media. This points out an active role of both intima and adventitia in the remodelling process of arterialized vein grafts. Alpha smooth muscle actin is associated with the contractile apparatus, and it is decreased in neointimal SMCs compared with medial SMCs [25] . Cultured media SMCs from porcine coronary arteries show a strong expression of alpha smooth muscle actin [26] . In our experiments, CNP-treated vein grafts showed a trend towards a lower expression of smooth muscle actin positive cells compared with controls.
An interesting finding of our study was that the adventitia and the neointima of the arterialized vein grafts seemed to be the zones of more remodelling activity than the media. This was particularly true for the expression of metallothionein and calponin in neointimal and adventitial cells. A perivascular pharmacological approach is supported by these results.
Conclusion
We conclude that perivascular application of CNP significantly inhibits neointimal hyperplasia of vein grafts in a mouse model. This reduction of vein graft disease is associated with a decreased amount of infiltration of CD-8 positive cells and an increased amount of calponin in the CNP-treated grafts. These results suggest that CNP may have a therapeutic potential for the treatment of clinical vein graft disease.
